Literature DB >> 12064368

Phenacetin O-deethylation in extrahepatic tissues of rats.

Z F Cui1, P He, M Luo, S Q Xia, M C Wu.   

Abstract

Phenacetin O-deethylation is a marker reaction of CYP450 1A2 activity. The drug-metabolizing enzyme is constitutively expressed in liver. In this study, an in vivo rat model for assessment of extrahepatic metabolism was used to investigate phenacetin O-deethylation and the alterations in the disposition of phenacetin due to the loss of liver function. Rats were divided into the model and normal control groups. The model was established according to our previously described method. The concentrations of phenacetin and its major metabolites acetaminophen, glucuronate-acetaminophen and sulfate-acetaminophen in plasma and urine were determined by HPLC. 30 min after intravenous administration of 0.16% phenacetin 10 mg x kg(-1), plasma acetaminophen in the model group was only 3.6% of that in the control group (0.09+/-0.04 microg x mL(-1) vs 2.49+/-0.85 microg x mL(-1), n = 8). 30 min after intragastric injection of 0.4% phenacetin 30 mg x kg(-1), plasma acetaminophen formation was very slight, about 8.6% of plasma phenacetin in the model group (0.74+/-0.43 microg x mL(-1) acetaminophen vs 8.57+/-8.42 microg x mL(-1) phenacetin) and 6.8% in the control group (1.06+/-0.59 microg x mL(-1) acetaminophen vs 15.47+/-7.21 microg x mL(-1) phenacetin, n = 8); no significant differences were observed in plasma phenacetin, total acetaminophen and the ratio of acetaminophen to phenacetin between control and model groups. In the urine collected for 3 h after intravenous administration of 0.16% phenacetin 10 mg x kg(-1), the total recovery of acetaminophen (as free, glucuronate- and sulfate-acetaminophen ) in the model group was 4.6% of that in the control group (4.47+/-4.27 microg vs 96.63+/-8.50 microg, n = 6), but phenacetin recovery in the model group was 9 times higher than that in the control group (15.03+/-17.72 microg vs 1.66+/-0.50 microg). The results indicate that phenacetin O-deethylation in the extrahepatic tissues and the first-pass metabolism of the probe compound seem to be negligible in rats, but the renal excretion of phenacetin, as a compensation, dramatically increases in model rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064368     DOI: 10.1007/BF03190424

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation.

Authors:  S Kudo; K Umehara; M Hosokawa; G Miyamoto; K Chiba; T Satoh
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

2.  An in vivo rat model for assessment of extrahepatic metabolism.

Authors:  H Ping; C Zhen-Fu; X Shao-Qing; L Ming; W Jian; Z Guo-Qing; Z Lin; L Lin-Fang; W Meng-Chao
Journal:  J Pharmacol Toxicol Methods       Date:  2001 May-Jun       Impact factor: 1.950

3.  Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects.

Authors:  S X Dong; Z Z Ping; W Z Xiao; C C Shu; A Bartoli; G Gatti; S D'Urso; E Perucca
Journal:  Ther Drug Monit       Date:  1998-08       Impact factor: 3.681

4.  Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice.

Authors:  J M Peters; H Morishima; J M Ward; C J Coakley; S Kimura; F J Gonzalez
Journal:  Toxicol Sci       Date:  1999-07       Impact factor: 4.849

5.  Metabolic activation of aromatic amines by human pancreas.

Authors:  K E Anderson; G J Hammons; F F Kadlubar; J D Potter; K R Kaderlik; K F Ilett; R F Minchin; C H Teitel; H C Chou; M V Martin; F P Guengerich; G W Barone; N P Lang; L A Peterson
Journal:  Carcinogenesis       Date:  1997-05       Impact factor: 4.944

6.  Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure.

Authors:  S Y Oh; C H Lee; Y S Ku
Journal:  J Pharm Pharmacol       Date:  2000-09       Impact factor: 3.765

7.  Bimodal distribution of renal cytochrome P450 3A activity in humans.

Authors:  B D Haehner; J C Gorski; M Vandenbranden; S A Wrighton; S K Janardan; P B Watkins; S D Hall
Journal:  Mol Pharmacol       Date:  1996-07       Impact factor: 4.436

Review 8.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

Authors:  D R Nelson; L Koymans; T Kamataki; J J Stegeman; R Feyereisen; D J Waxman; M R Waterman; O Gotoh; M J Coon; R W Estabrook; I C Gunsalus; D W Nebert
Journal:  Pharmacogenetics       Date:  1996-02

9.  Sources of interindividual variations in acetaminophen and antipyrine metabolism.

Authors:  R M Nash; L Stein; M B Penno; G T Passananti; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

10.  Quantitative determination of phenacetin and its metabolite acetaminophen by GLC-chemical ionization mass spectrometry.

Authors:  W A Garland; K C Hsiao; E J Pantuck; A H Conney
Journal:  J Pharm Sci       Date:  1977-03       Impact factor: 3.534

View more
  3 in total

Review 1.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

2.  Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma.

Authors:  Xiaohua Pan; Xiaodong Li; Liqing Cui; Qianwei Wang
Journal:  Med Sci Monit       Date:  2017-05-29

3.  Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo.

Authors:  Sang-Bum Kim; Kyu-Sang Kim; Heon-Min Ryu; Seong-Ho Hong; Bo-Kyoung Kim; Dae-Duk Kim; Jin Woo Park; In-Soo Yoon
Journal:  Molecules       Date:  2018-06-17       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.